<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We scored absolute numbers of circulating CD34+ cells by a highly sensitive triple-color flow cytometric analysis using CD45 monoclonal antibody, CD34 monoclonal antibody and <z:chebi fb="0" ids="51240">propidium iodide</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>Forty-one patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (RA: 27, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>: 1, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>: 6, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t: 3,<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>: 4), 12 patients with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (AA) and 36 age-adjusted <z:mpath ids='MPATH_458'>normal</z:mpath> subjects were studied </plain></SENT>
<SENT sid="2" pm="."><plain>RA had significantly decreased numbers of cells expressing CD34 (0.21 +/- 0.29 x 10(6)/l) compared with <z:mpath ids='MPATH_458'>normal</z:mpath> subjects (0.81 +/- 0.36 x 10(6)/l)(P &lt; 0.001) </plain></SENT>
<SENT sid="3" pm="."><plain>This low number of CD34+ cells in RA resembles the case of AA (0.39 +/- 0.73 x 10(6)/l) </plain></SENT>
<SENT sid="4" pm="."><plain>In light-scatter analysis, the CD34+ cells of RA patients were distributed mainly in low forward scatter (FSC) (lymphocyte region) </plain></SENT>
<SENT sid="5" pm="."><plain>In contrast, the CD34+ cell counts were extremely high in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> (46.54 +/- 71.37 x 10(6)/l) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t (57.00 +/- 52.36 x 10(6)/l) (P &lt; 0.001) and the CD34+ cells were observed in high FSC (blast region).<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> patients showed moderately increased numbers of CD34+ cells (3.69 +/- 4.64 x 10(6)/l) </plain></SENT>
<SENT sid="6" pm="."><plain>Thus, there was a distinct difference in cell size and number of circulating CD34+ cells between RA and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t </plain></SENT>
<SENT sid="7" pm="."><plain>In univariate and multivariate analysis, a high CD34+ cell count (&gt; or = 1.0 x 10(6)/l) was a poor prognostic factor </plain></SENT>
<SENT sid="8" pm="."><plain>This method allows one to distinguish RA from other <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> subtypes more reliably than by <z:mp ids='MP_0000002'>morphology</z:mp> alone and provides early signs of progression to <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> </plain></SENT>
</text></document>